Natalizumab/Tsyabri vs. CCSVI: Good Science vs. Bad Science

In response to someone's comment re comparing CCSVI to Tysabri or Natalizumab. I have embedded the graph. It is clear the trends are very different; Tysabri/Natalizumab dwarfs that of CCSVI. In epidemiological terms we would say that Tysabri/Natalizumab is endemic, i.e. the number of searches is high, but has reached a stable number of searches. In comparison, CCSVI has peaked and is petering out! To extinction possibly? Who knows only time will tell.